KR20220119147A - Cd163 항체 또는 결합 단백질 - Google Patents

Cd163 항체 또는 결합 단백질 Download PDF

Info

Publication number
KR20220119147A
KR20220119147A KR1020227025626A KR20227025626A KR20220119147A KR 20220119147 A KR20220119147 A KR 20220119147A KR 1020227025626 A KR1020227025626 A KR 1020227025626A KR 20227025626 A KR20227025626 A KR 20227025626A KR 20220119147 A KR20220119147 A KR 20220119147A
Authority
KR
South Korea
Prior art keywords
sequence
antibody
amino acid
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227025626A
Other languages
English (en)
Korean (ko)
Inventor
찰스 오웬
하피드 압델라리 벤차위
크리스틴 테이트-버카드
Original Assignee
에코 애니몰 헬스 엘티디
에코 애니몰 헬스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에코 애니몰 헬스 엘티디, 에코 애니몰 헬스 엘티디 filed Critical 에코 애니몰 헬스 엘티디
Publication of KR20220119147A publication Critical patent/KR20220119147A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227025626A 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질 Ceased KR20220119147A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919294.7 2019-12-24
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
KR20220119147A true KR20220119147A (ko) 2022-08-26

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025626A Ceased KR20220119147A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질

Country Status (13)

Country Link
US (1) US20230203185A1 (https=)
EP (1) EP4081542A1 (https=)
JP (1) JP7702952B2 (https=)
KR (1) KR20220119147A (https=)
CN (1) CN121873247A (https=)
BR (1) BR112022012362A2 (https=)
CL (1) CL2022001706A1 (https=)
CO (1) CO2022010294A2 (https=)
DO (2) DOP2022000136A (https=)
GB (1) GB201919294D0 (https=)
MX (1) MX2022007957A (https=)
PE (1) PE20230384A1 (https=)
WO (1) WO2021130502A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
WO2024156888A1 (en) * 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3331355T3 (fi) * 2015-08-06 2024-06-17 Univ Missouri Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
JP2023508674A (ja) 2023-03-03
CA3162664A1 (en) 2021-07-01
JP7702952B2 (ja) 2025-07-04
PE20230384A1 (es) 2023-03-06
EP4081542A1 (en) 2022-11-02
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CL2022001706A1 (es) 2023-05-26
BR112022012362A2 (pt) 2022-09-06
GB201919294D0 (en) 2020-02-05
CO2022010294A2 (es) 2022-10-31
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CN121873247A (zh) 2026-04-17
CN115151569A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7702952B2 (ja) Ｃｄ１６３抗体または結合タンパク質
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
US20240376180A1 (en) Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein
CN111225925A (zh) 抗hla-dq2.5抗体
Apostolopoulos et al. The isolation and purification of biologically active recombinant and native autoantigens for the study of autoimmune disease
US11117976B2 (en) Compositions and methods for regulating erythropoiesis
CN113698487B (zh) 抗人ace2单克隆抗体及其应用
AU2015286604B2 (en) Substances and methods for the use in prevention and/or treatment in Huntington's disease
CA3162664C (en) Cd163 antibodies or binding proteins
CN115151569B (zh) Cd163抗体或结合蛋白
US20260085129A1 (en) Cd163 binding protein
CN106687475A (zh) 用于预防和/或治疗亨廷顿氏病的物质和方法
EP3833442A2 (en) Antibodies that bind cd277 and uses thereof
TW202328176A (zh) 抗-sars-cov-2抗體組成物及其用途
WO2022132887A1 (en) Human monoclonal antibodies targeting the sars-cov-2 spike protein
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
WO2023145874A1 (ja) コロナウイルスに対する新規なモノクローナル抗体
TW202309069A (zh) 糖鏈修飾rbd及其用途
WO2023178182A1 (en) Compositions and methods for detection and treatment of coronavirus infection
Coelho Isolation of human recombinant antibodies anti-SARS-CoV-2 by synthetic methods
CN118496359A (zh) 一种抗Siglec-15抗体及其应用
WO2026021281A1 (zh) 一种全人源抗狂犬病毒的中和抗体及其应用
CN120607613A (zh) 一种新型冠状病毒中和抗体变体及其应用
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601